Clinical Trial Update: Pyrotinib in HER2-positive Early Breast Cancer [NA]

View source ↗

Summary

A clinical trial update indicates a study of Pyrotinib for HER2-positive early breast cancer is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Nie Jianyun | Conditions: HER2-positive Breast Cancer | NA | Status: NOT_YET_RECRUITING